Intelligence / Healthtech / PMA Approvals / Allergan
Approvalsdevice change approved (PMA)4 Nov 2026
Allergan
4 Nov 2026: Device change approved (PMA) · Juvéderm Ultra XC; Juvéderm Ultra Plus XC. Recorded in the openFDA device PMA data.
- Decided
- 4 Nov 2026
- Device
- Juvéderm Ultra XC; Juvéderm Ultra Plus XC
- Specialty
- General, Plastic Surgery
- Type
- Supplement (Normal 180 Day Track)
- Reason
- Change Design/Components/Specifications/Material
- Reference
- P050047 S106
- Location
- Irvine, CA
What this signal means
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Allergan
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Allergan in our registers.
More in General, Plastic Surgery
PMA Approvals
7 NovBaxter Healthcare Corporationdevice change approved (PMA) · PerClot Absorbable Hemostatic Powder Accessory TipsApprovals4 NovMerz North America, INC.device change approved (PMA) · Belotero Volume (+) LidocaineApprovals4 NovTiger Aesthetics Medical, LLCdevice change approved (PMA) · Sientra® Silicone Gel Breast ImplantsApprovals23 OctAdvanced Medical Solutions Limiteddevice change approved (PMA) · LIQUIFIX FIX8 Laparoscopic Hernia Mesh Fixation (HMF) Device; LIQUIFIX Precision Open Hernia Mesh Fixation DeviceApprovals8 OctCroma-Pharma GMBHdevice change approved (PMA) · saypha® ChiQApprovals7 OctCroma-Pharma GMBHdevice change approved (PMA) · saypha® ChiQApprovals
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.